SavedAdd your journal

Journals / Annals of Health Sciences Research / 2014 / Cilt: 3 - Sayı: 1

Fixed Combination Therapy in Glaucoma

Glokomda Sabit Kombine Tedaviler

Murat Atabey ÖZER
Pages
33–38
Publication Date
2014-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The basic features, efficacy, tolerability, etc. of fixed combination glaucoma drugs which have been currently used in our country were investigated in this article

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Initial treatment of glaucoma is based on the topical use of one or more of the glaucoma drugs to reduce intraocular pressure.
📊
Key Findings & Data:Double or triple treatments can also be used separately as well as a fixed combination of them.
💡
Conclusion & Impact:The basic features, efficacy, tolerability, etc. of fixed combination glaucoma drugs which have been currently used in our country were investigated in this article
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Glokom · Göz Içi Basıncı · Sabit Kombine Tedavi

Abstract

Initial treatment of glaucoma is based on the topical use of one or more of the glaucoma drugs to reduce intraocular pressure. Double or triple drug treatments are applied where a topical medicament for treatment does not suffice. Double or triple treatments can also be used separately as well as a fixed combination of them. Fixed combination therapies are more advantageous than the combination use of multiple drugs with respect to posology, ease of use and side effects. The basic features, efficacy, tolerability, etc. of fixed combination glaucoma drugs which have been currently used in our country were investigated in this article

Özet

Glokomun başlangıç tedavisi göz içi basıncını düşürmek üzere bir veya daha fazla glokom ilacının topikal kullanılmasına dayanmaktadır. Tedavide bir topikal ilacın yeterli olmadığı durumlarda, ikili veya üçlü ilaç tedavileri uygulanmaktadır. İkili veya üçlü tedaviler ayrı ayrı uygulanabildiği gibi sabit kombine ilaçlar şeklinde de kullanılabilmektedir. Sabit kombinasyon tedavilerinin, pozoloji, kullanım rahatlığı ve yan etkiler açısından birden çok ilacın bir arada kullanımına göre daha avantajlı olduğu gözükmektedir. Bu makalede glokomda ülkemizde halihazırda kullanılmakta olan sabit kombinasyon ilaçların temel özellikleri incelenmiş, etkinlik, tolerabilite gibi özellikleri araştırılmıştır

🔖

Cite This Article

ÖZER, M. A. (2014). Fixed Combination Therapy in Glaucoma. Annals of Health Sciences Research, Cilt: 3 - Sayı: 1, 33–38. https://ajindex.com/articles/824876

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Hollows FC, Graham PA. İntraocular pressure, glaucoma, and glaucoma suspects in a defined population. Br J Ophthalmol 1966; 50: 570-86. Göz hastalıkları. Bengisu Ü, editor. Glokom. Ankara: Palme Yayınları; 1998: p.139-58. European Glaucoma Society.: Terminology and Guidelines for Glaucoma, 3rd edition. 2008.
  2. Leske MC, Heijl A, Hussein M, et al.: Factors of glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2002; 121: 48-56.
  3. Choudhri S, Wand M, Shields MB. A comparison of dorzolamid-timolol combination versus the concomitant drugs. Am J Ophthalmology 2000; 130: 832-3.
  4. Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: one- year randomized trial. Arch Ophthalmol 2002; 120: 915-22.
  5. Lee PS, Gagliuso DJ, Serle JB. Medical therapy for glaucoma. Choplin NT, Lundy DC, editors. Atlas of Glaucoma. 2nd edition London: Informa Healthcare; 2007: p.228-30.
  6. Lippo EA, Carlson LE, Ehinger B, Eriksson LO, Finnström K, Holmin C, et al.Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992; 100: 495. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), Dorzolamide Study Group. Arch Ophthalmol 1995; 113: 985-6. betaxolol. International Shields BM. Carbonic anhydrase inhibitors. Williams and Wilkins Texbook of Glaucoma. 1st editon. Baltimore; 1998. p. 431-9. Shields MB. Adrenergic stimulators. Williams and Wilkins Texbook of Glaucoma. 1st editon. Baltimore; Choplin NT, Lundy DC, editors. Atlas of Glaucoma. 2nd edition London: Informa Healthcare; 2007: p.228- 30. Hejkal TW, Camras CB. Prostaglandine analogs in the treatment of glaucoma. Semin Ophthalmol 1999; 14: 114-23.
  7. Woodward DF, Kraus AH, Chen J Chen J, Lai RK, Spada CS, Burk RM, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2001; 45: 337-45.
  8. Kass MA, Heuer DK, Higginbotham EJ, et al.: The Ocuar Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120: 701-13.
  9. Lichter PR, Musch DC, Gilespie BW, et al.: Interm clinical outcomes in the Collaborative Initial Glaucoma treatment Study comparing inital treatment randomized to medications or surgery. Ophthalmol 2001; 108: 1943-53.
  10. Clineschmidt CM, Wiliams RD, Snyder E, et al.: A randomized trial in patients inade